News
Medlogics Receives Approval to Begin Selling Bare Metal Stent in Europe
Santa Rosa, CA, February 01, 2008; - Medlogics Device Corporation has announced it has received CE Mark approval for the COBRA Coronary Stent System. COBRA is a cobalt super alloy stent designed with ultra-thin struts. Richard Klein, Medlogics’ President and co-founder states: “Due to its novel architecture, COBRA has a very low crossing profile with struts that are significantly thinner than competitive devices on the market. As a result, we believe that Cobra will benefit patients by allowing physicians to more easily cross difficult lesions and impart less injury with improved clinical results.” Medlogics plans on immediate sales of the Cobra Coronary Stent System in Western Europe. Medlogics has several products in the pipeline and the CE Mark approval of COBRA is a significant milestone as it also provides the platform for the company’s DES program.
About Medlogics Device Corporation
Medlogics, with headquarters in Santa Rosa, CA, is dedicated to providing safe and effective clinically superior devices to patients and their physicians worldwide. Medlogics was founded upon the principle of designing innovative, best-in-class
solutions to local drug delivery. Medlogics is currently focused on developing a next-generation drug-eluting stent technology to treat coronary artery disease using a novel stent and drug-delivery approach. To help accomplish this goal, Medlogics has vertically
integrated drug-eluting coating, stent, and catheter research & development, and manufacturing.
CONTACT:
Kalei Hampson, Marketing Director, Medlogics Device Corporation; +1-707-545-5700
KHampson@MedlogicsDC.com
www.MedlogicsDC.com